The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
Open accessAbstract
Purpose: Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. Patients and Methods: Clinically annotated, microarray data from 784 early-stage breast cancers were identified, and prospectively defined, age-specific cohorts (young: ≤ 45 years, n = 200; older: ≥ 65 years, n = 211) were compared by prognosis, clinicopathologic variables, mRNA expression values, single-gene analysis, and gene set enrichment analysis (GSEA). Univariate and multivariate analyses were performed. Results: Using clinicopathologic variables, young women illustrated lower estrogen receptor (ER) positivity (immunohistochemistry [IHC], P = .027), larger tumors (P = .012), higher human epidermal growth factor receptor 2 (HER-2) overexpression (IHC, P = .075), lymph node positivity (P = .008), higher grade tumors (P < .0001), and trends toward inferior disease-free survival (DFS; hazard ratio = 1.32; P = .094). Using genomic expression analysis, tumors arising in young women had significantly lower ERα mRNA (P < .0001), ERβ (P = .02), and progesterone receptor (PR) expression (P < .0001), but higher HER-2 (P < .0001) and epidermal growth factor receptor (EGFR) expression (P < .0001). Exploratory analysis (GSEA) revealed 367 biologically relevant gene sets significantly distinguishing breast tumors arising in young women. Combining clinicopathologic and genomic variables among tumors arising in young women demonstrated that younger age and lower ERβ and higher EGFR mRNA expression were significant predictors of inferior DFS. Conclusion: This large-scale genomic analysis illustrates that breast cancer arising in young women is a unique biologic entity driven by unifying oncogenic signaling pathways, is characterized by less hormone sensitivity and higher HER-2/EGFR expression, and warrants further study to offer this poor-prognosis group of women better preventative and therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Genomic signatures to guide the use of chemotherapeutics
Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M. J., Petersen, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1491 · Cited by 593
Self-citationRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Previous studies report lymph node positivity among 40% to 55% of patients with triple-negative breast cancer versus 30% within our complete data set.(33,35) Because triple-negative breast cancer is a more aggressive phenotype, our data set likely represent a better prognosis sample of patients with an overall lower l…”
Background
Research works printed but not linked: 7
- 10.1016/S0959-8049(97)89017-X · doi:10.1016/s0959-8049(97)89017-x
- 10.1038/bjc.1997.223 · doi:10.1038/bjc.1997.223
- 10.1016/S0140-6736(05)70933-8 · doi:10.1016/s0140-6736(05)70933-8 · Paper page
- Kim C, Tang G, Baehner F, et al: A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17 , 2006 (abstr 3116)
- 10.1023/A:1006498721508 · doi:10.1023/a:1006498721508
- 10.1093/jnci/djh115 · doi:10.1093/jnci/djh115
- 10.1097/00008571-200204000-00012 · doi:10.1097/00008571-200204000-00012
Cited by
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Fan, L., Strasser-Weippl, K., Li, J.-J., St Louis, J., Finkelstein, D. M., Yu, K.-D., Chen, W.-Q., Shao, Z.-M., & Goss, P. E. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70567-9 · Cited by 1,397
Breast Cancer Before Age 40 Years
Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.03.001 · Cited by 791
Self-citationEpidemiology of breast cancer in Indian women: Breast cancer epidemiology
Malvia, S., Bagadi, S. A., Dubey, U. S., & Saxena, S. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12661 · Cited by 784
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3481-4 · Cited by 612
Breast cancer in young women: an overview
Anastasiadi, Z., Lianos, G. D., Ignatiadou, E., Harissis, H. V., & Mitsis, M. (2017) · Updates in Surgery · doi:10.1007/s13304-017-0424-1 · Cited by 603
Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Ugai, T., Sasamoto, N., Lee, H.-Y., Ando, M., Song, M., Tamimi, R. M., Kawachi, I., Campbell, P. T., Giovannucci, E. L., Weiderpass, E., et al. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00672-8 · Cited by 603
Chang, J.-W., Kuo, W.-H., Lin, C.-M., Chen, W.-L., Chan, S.-H., Chiu, M.-F., Chang, I.-S., Jiang, S.-S., Tsai, F.-Y., Chen, C.-H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0253-9 · Cited by 540
Kuhl, C., Weigel, S., Schrading, S., Arand, B., Bieling, H., König, R., Tombach, B., Leutner, C., Rieber-Brambs, A., Nordhoff, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0839 · Cited by 501
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
Fredholm, H., Eaker, S., Frisell, J., Holmberg, L., Fredriksson, I., & Lindman, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007695 · Cited by 495
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.012 · Cited by 495
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., Eccles, B., Gerty, S., Durcan, L. T., Jones, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 481
Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy
Arvold, N. D., Taghian, A. G., Niemierko, A., Abi Raad, R. F., Sreedhara, M., Nguyen, P. L., Bellon, J. R., Wong, J. S., Smith, B. L., & Harris, J. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1105 · Cited by 452
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
Gnerlich, J. L., Deshpande, A. D., Jeffe, D. B., Sweet, A., White, N., & Margenthaler, J. A. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.12.001 · Cited by 441
Azim, H. A., Michiels, S., Bedard, P. L., Singhal, S. K., Criscitiello, C., Ignatiadis, M., Haibe-Kains, B., Piccart, M. J., Sotiriou, C., & Loi, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2599 · Cited by 399
Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., Giordano, M., Garrone, O., Pronzato, P., Bighin, C., et al. (2011) · JAMA · doi:10.1001/jama.2011.991 · Cited by 351
Epidemiology and prognosis of breast cancer in young women.
Assi, H., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., & Saghir, N. S. E. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.05.24 · Cited by 306
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Gerber, B., von Minckwitz, G., Stehle, H., Reimer, T., Felberbaum, R., Maass, N., Fischer, D., Sommer, H. L., Conrad, B., Ortmann, O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5704 · Cited by 297
Treatment of breast cancer during pregnancy: an observational study
Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., Fehm, T., Van Calsteren, K., Linn, S. C., Schlehe, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70261-9 · Cited by 290
Collins, L. C., Marotti, J. D., Gelber, S., Cole, K., Ruddy, K., Kereakoglow, S., Brachtel, E. F., Schapira, L., Come, S. E., Winer, E. P., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1872-9 · Cited by 271
Anders, C. K., Fan, C., Parker, J. S., Carey, L. A., Blackwell, K. L., Klauber-DeMore, N., & Perou, C. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9199 · Cited by 263
Self-citationNarod, S. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.102 · Cited by 254
An iron regulatory gene signature predicts outcome in breast cancer
Miller, L. D., Coffman, L. G., Chou, J. W., Black, M. A., Bergh, J., D'Agostino, R., Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1870 · Cited by 202
“It has been reported that breast cancer in younger women represents a unique biological entity, with increased expression of genes related to hypoxia and other signaling pathways (33).”
Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
Jenkins, E. O., Deal, A. M., Anders, C. K., Prat, A., Perou, C. M., Carey, L. A., & Muss, H. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0184 · Cited by 165
Self-citationEvans, D. G. R., Moran, A., Hartley, R., Dawson, J., Bulman, B., Knox, F., Howell, A., & Lalloo, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605606 · Cited by 52
A link between premenopausal iron deficiency and breast cancer malignancy
Jian, J., Yang, Q., Shao, Y., Axelrod, D., Smith, J., Singh, B., Krauter, S., Chiriboga, L., Yang, Z., Li, J., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-307 · Cited by 37
“By comparing the gene expression profile from young BC patients to those from mice fed iron deficient diet, [1,13] overlaps of genes centered on hypoxia, angiogenesis, and metastasis.”
BackgroundHormone replacement therapy and women with premature menopause–a cancer survivorship issue
King, J., Wynne, C. H., Assersohn, L., & Jones, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.007 · Cited by 34
Metadata
- Authors
- Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., Wang, Y., Marcom, P. K., Marks, J. R., Febbo, P. G., Nevins, J. R., Potti, A., & Blackwell, K. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-10
- Volume
- 26
- Issue
- 20
- Pages
- 3324-3330
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161849165
- Cited by
- 911
- References
- 37
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.